Physician profile
Michael C Bang
NPI 1366571309
$2,295.30
in general payments reported to CMS, 2019-2025
18 companies · $522 in 2025
The $522 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.77 · 2021: $19.97 · 2022: $175 · 2023: $382 · 2024: $1,176 · 2025: $522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,067 · Travel and Lodging: $13.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,066.99 |
| Travel and Lodging | $13.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $476.91 | 2023-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $320.18 | 2019-2024 | Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $296.69 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $226.32 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $152.79 | 2023-2025 | |
| Amgen INC. | $137.71 | 2024-2025 | Krystexxa, Otezla, Repatha |
| Exact Sciences Corporation | $134.71 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $105.18 | 2022-2025 | Capvaxive, Gardasil 9 |
| Astellas Pharma US INC | $102.23 | 2024 | Veozah |
| Phadia US INC. | $84.66 | 2023-2025 | Immunocap |
| Novo Nordisk INC | $49.03 | 2025 | |
| Seqirus USA INC | $45.11 | 2021-2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Kowa Pharmaceuticals America, INC. | $42.83 | 2025 | Zoryve |
| Horizon Therapeutics Plc | $33.50 | 2022-2023 | Krystexxa |
| Alexion Pharmaceuticals, INC. | $25.74 | 2024 | Strensiq |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $23.62 | 2023 | Aptima, Thinprep 2000 Processor |
| Sanofi-Aventis U.S. LLC | $22.38 | 2024 | |
| Becton, Dickinson and Company | $15.71 | 2024 | Bd Onclarity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Bang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.